Company Description
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.
The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Contact Details
Address: 112-970 Burrard Street, Unit 1290 Vancouver, BC V6Z 2R4 Canada | |
| Phone | 778-731-1711 |
| Website | nervgen.com |
Stock Details
| Ticker Symbol | NGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001751912 |
| CUSIP Number | 64082X203 |
| ISIN Number | CA64082X2032 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adam H. Rogers M.D. | President, Chief Executive Officer and Chairman |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder and Independent Director |
| Dr. Randall E. Kaye M.D. | Chief Medical Advisor and Director |
| Dr. Keith A. Vendola M.B.A., M.D. | Chief Financial Officer |
| Shamim Ruff M.S. | Chief Regulatory Affairs Officer |
| Christine McSherry | Senior Vice President of Patient Advocacy and Clinical Affairs |